Midostaurin companion diagnostic - Invivoscribe/Novartis Oncology

Drug Profile

Midostaurin companion diagnostic - Invivoscribe/Novartis Oncology

Alternative Names: FLT3 companion diagnostic; LeukoStratCDx FLT3 Mutation Assay; PKC 412 companion diagnostic - Invivoscribe/Novartis

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator Takara Bio
  • Developer Invivoscribe Technologies; Novartis Oncology
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Acute myeloid leukaemia

Most Recent Events

  • 28 Apr 2017 Registered for Acute myeloid leukaemia (Diagnosis) in USA (unspecified route)
  • 14 Nov 2016 Preregistration for Acute myeloid leukaemia (Diagnosis) in European Union (unspecified route)
  • 14 Nov 2016 Preregistration for Acute myeloid leukaemia (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top